Uniting researchers and clinicians to treat infectious diseases with bacteriophages and other innovative treatments.

Aims and objectives

The ESCMID Study Group for Non-Traditional Antibacterial Therapy (ESGNTA) brings together professionals from various expertise dedicated to advancing the use of bacteriophages and other new non-traditional therapeutic approaches to treat infectious diseases. Their mission includes: 

• Developing microbiological guidelines and supporting the clinical use of phages and phage-derived products, via clinical trials and compassionate use
• Identifying bacterial pathogens and infectious disease indications where non-traditional antibacterials, including bacteriophage therapies, may lead to cure or improved clinical outcomes
• Increasing knowledge and fostering research on phage-derived enzymes, especially lysins, to identify the optimal carriers and applications in clinical settings, such as gels and nanoparticles
• Creating a network and promoting the establishment of academic phage therapy centres across European countries, based on the models developed in Belgium, France, Israel, Australia, and the USA